319: BioMarin's executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion's AI bona fides
The Readout Loud
00:00
Innovating Drug Development with AI
This chapter explores Recursion Pharmaceuticals' unique approach to AI-driven drug development and its notable partnership with Nvidia. It highlights the company's challenges in the traditional biotech landscape, the recent merger with Accentia, and the ongoing skepticism about the future of AI in drug discovery. Furthermore, it reflects on the ambitious goals of Recursion and the industry's cautious optimism about the potential impact of AI in transforming drug development.
Transcript
Play full episode
